Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• KRAS is the most frequently mutated oncogene in human cancers.
• RAS proteins have historically been challenging to target with drugs, earning them the 'undruggable' designation.

Purpose of the Study:

• To provide an in-depth analysis of RAS structure, dynamics, mutational activation, and signaling.
• To explore potential mechanisms of action for effective RAS inhibitors.
• To review recent developments in direct RAS inhibitors and discuss future research directions.

Main Methods:

• Literature review of recent reports on direct RAS inhibitors.
• Analysis of KRAS structure, dynamics, and signaling pathways.
• Exploration of drug discovery approaches targeting RAS.

Main Results:

• Recent technological advancements and novel drug discovery strategies are reviving the possibility of targeting KRAS directly.
• Several promising direct RAS inhibitors have been reported in recent studies.

Conclusions:

• Despite past challenges, direct targeting of KRAS is becoming increasingly feasible.
• Continued research into RAS inhibitors holds significant promise for cancer therapy development.